Peptide receptor radionuclide therapy in neuroendocrine tumours: advances, combination strategies, and future directions - PubMed
6 days ago
- #PRRT
- #Neuroendocrine tumors
- #Targeted therapy
- PRRT is a key treatment for advanced, SSTR-positive neuroendocrine tumors (NETs).
- The NETTER-1 trial showed [177Lu]Lu-DOTATATE improves progression-free survival and quality of life in midgut NETs.
- NETTER-2 supports first-line PRRT use in Grade 2 and 3 GEP-NETs (Ki-67 ≥ 10 ≤ 55%).
- New developments include SSTR antagonists, targeted α-particle therapies, and combination strategies with chemotherapy, DNA-repair inhibitors, and immunotherapy.
- Innovations in radiopharmaceutical chemistry include CCK2R-targeted compounds for rare NETs like MTC and SCLC.
- Future directions focus on expanding PRRT indications, integrating α-emitters, improving safety, and developing personalized theragnostic ligands.